INTRON A SOLN Rx

Select the drug indication to add to your list

INTRON A SOLN

Kaposi's sarcoma
Leukemias, lymphomas, and other hematologic cancers
Melanoma and other skin cancers
Viral infections
Warts
Only 4 drugs may be compared at once

Generic Name and Formulations:

Interferon alfa-2b, recombinant; 10 million IU, 18 million IU, 25 million IU; per vial; for inj; contains m-cresol.

Select therapeutic use:

Indications for INTRON A SOLN:

AIDS-related Kaposi's sarcoma.

Adult:

Use appropriate preparation and route: see full labeling. Use SC route if platelets <50,000/mm3. 30 million IU/m2 IM or SC three times weekly; continue until rapid disease progression or maximal response achieved after 16 weeks; reduce dose by ½ or suspend therapy if severe adverse reactions occur; discontinue if persists.

Children:

Not recommended.

Contraindications:

Decompensated liver disease. Autoimmune hepatitis.

Warnings/Precautions:

May cause or exacerbate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, or infectious disorders: monitor closely, discontinue if they worsen. Severe psychiatric disorders (esp. depression). Cardiovascular or pulmonary disease. Severe myelosuppression; discontinue if neutrophil count <0.5 X109/L or platelets 25X109/L. Permanently discontinue if severe (Grade 3) hepatic injury or decompensation (Child-Pugh score >6 [Class B and C]) develop. Thyroid abnormalities; discontinue if uncontrolled by medication. Diabetes. Coagulation disorders. Maintain adequate hydration. Monitor blood, thyroid, visual and liver function before and during therapy; EKG in cardiovascular disease and cancer patients. Psoriasis. Renal dysfunction. Transplant recipients. Elderly. Debilitated. Pregnancy (Cat.C). Nursing mothers: not recommended.

Interactions:

Caution with myelosuppressives, and drugs that can exacerbate depression. May potentiate theophylline (may double its levels).

See Also:

INTRON A

Pharmacological Class:

Alpha interferon.

Adverse Reactions:

Flu-like symptoms (fever, headache, myalgia, fatigue); hepatic, hematologic, respiratory, skin, genitourinary system, CNS, cardiovascular, endocrine (esp. thyroid), GI, or visual disorders; colitis, hypertriglyceridemia, pancreatitis, infections, injection site reactions, dental and periodontal disorders; others (see full labeling).

How Supplied:

Pwd (w. diluent): 10million, 18million, 50million IU/vial—1; Soln (multidose vials): 18million, 25million IU/vial—1

Indications for INTRON A SOLN:

Hairy cell leukemia. Initial treatment of clinically aggressive follicular Non-Hodgkin's lymphoma in conjunction with anthracycline-containing combination chemotherapy.

Adult:

Use SC route if platelets <50,000/mm3. Hairy cell leukemia: 2 million IU/m2 IM or SC 3 times a week for up to 6 months. Follicular lymphoma: 5 million IU SC 3 times a week for up to 18 months in conjunction with anthracycline-containing chemotherapy regimen and following completion of the chemotherapy regimen. See full labeling for appropriate preparation and route and for dose adjustments.

Children:

Not recommended.

Contraindications:

Decompensated liver disease. Autoimmune hepatitis.

Warnings/Precautions:

May cause or exacerbate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, or infectious disorders: monitor closely, discontinue if they worsen. Severe psychiatric disorders (esp. depression). Cardiovascular or pulmonary disease. Severe myelosuppression; discontinue if neutrophil count <0.5 X109/L or platelets 25X109/L. Permanently discontinue if severe (Grade 3) hepatic injury or decompensation (Child-Pugh score >6 [Class B and C]) develop. Thyroid abnormalities; discontinue if uncontrolled by medication. Diabetes. Coagulation disorders. Maintain adequate hydration. Monitor blood, thyroid, visual and liver function before and during therapy; EKG in cardiovascular disease and cancer patients. Psoriasis. Renal dysfunction. Transplant recipients. Elderly. Debilitated. Pregnancy (Cat.C). Nursing mothers: not recommended.

Interactions:

Caution with myelosuppressives, and drugs that can exacerbate depression. May potentiate theophylline (may double its levels).

See Also:

INTRON A

Pharmacological Class:

Alpha interferon.

Adverse Reactions:

Flu-like symptoms (fever, headache, myalgia, fatigue); hepatic, hematologic, respiratory, skin, genitourinary system, CNS, cardiovascular, endocrine (esp. thyroid), GI, or visual disorders; colitis, hypertriglyceridemia, pancreatitis, infections, injection site reactions, dental and periodontal disorders; others (see full labeling).

How Supplied:

Pwd (w. diluent): 10million, 18million, 50million IU/vial—1; Soln (multidose vials): 18million, 25million IU/vial—1

Indications for INTRON A SOLN:

Malignant melanoma.

Adult:

Induction: 20million IU/m2 IV over 20 mins, 5 consecutive days per week, for 4 weeks. Maintenance: 10 million IU/m2 SC 3 times per week for 48 weeks. See full labeling for appropriate preparation and route and for dose adjustments.

Children:

Not recommended.

Contraindications:

Decompensated liver disease. Autoimmune hepatitis.

Warnings/Precautions:

May cause or exacerbate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, or infectious disorders: monitor closely, discontinue if they worsen. Severe psychiatric disorders (esp. depression). Cardiovascular or pulmonary disease. Severe myelosuppression; discontinue if neutrophil count <0.5 X109/L or platelets 25X109/L. Permanently discontinue if severe (Grade 3) hepatic injury or decompensation (Child-Pugh score >6 [Class B and C]) develop. Thyroid abnormalities; discontinue if uncontrolled by medication. Diabetes. Coagulation disorders. Maintain adequate hydration. Monitor blood, thyroid, visual and liver function before and during therapy; EKG in cardiovascular disease and cancer patients. Psoriasis. Renal dysfunction. Transplant recipients. Elderly. Debilitated. Pregnancy (Cat.C). Nursing mothers: not recommended.

Interactions:

Caution with myelosuppressives, and drugs that can exacerbate depression. May potentiate theophylline (may double its levels).

See Also:

INTRON A

Pharmacological Class:

Alpha interferon.

Adverse Reactions:

Flu-like symptoms (fever, headache, myalgia, fatigue); hepatic, hematologic, respiratory, skin, genitourinary system, CNS, cardiovascular, endocrine (esp. thyroid), GI, or visual disorders; colitis, hypertriglyceridemia, pancreatitis, infections, injection site reactions, dental and periodontal disorders; others (see full labeling).

How Supplied:

Pwd (w. diluent): 10million, 18million, 50million IU/vial—1; Soln (multidose vials): 18million, 25million IU/vial—1

Indications for INTRON A SOLN:

Chronic hepatitis C. Chronic hepatitis B.

Adult:

Use appropriate preparation and route: see full labeling. Use SC route if platelets <50,000/mm3. Hepatitis C: 3 million IU IM or SC three times weekly for 16 weeks; if tolerated with normalization of ALT, continue to 18–24 months (72–96 weeks). Hepatitis B: 5 million IU daily or 10million IU IM or SC three times weekly for 16 weeks; reduce dose by ½ or interrupt dose if WBCs, granulocyte or platelet count decreases.

Children:

<1yr: not recommended. Use appropriate preparation and route: see full labeling. ≥1yr of age for chronic hepatitis B: 3million IU/m2 SC three times weekly for 1 week, then increase to 6million IU/m2 (max 10 million IU) three times weekly for a total of 16–24 weeks; reduce dose by ½ or interrupt dose if WBCs, granulocytes or platelet counts decrease.

Contraindications:

Decompensated liver disease. Autoimmune hepatitis.

Warnings/Precautions:

May cause or exacerbate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, or infectious disorders: monitor closely, discontinue if they worsen. Severe psychiatric disorders (esp. depression). Cardiovascular or pulmonary disease. Severe myelosuppression; discontinue if neutrophil count <0.5 X109/L or platelets 25X109/L. Permanently discontinue if severe (Grade 3) hepatic injury or decompensation (Child-Pugh score >6 [Class B and C]) develop. Thyroid abnormalities; discontinue if uncontrolled by medication. Diabetes. Coagulation disorders. Maintain adequate hydration. Monitor blood, thyroid, visual and liver function before and during therapy; EKG in cardiovascular disease and cancer patients. Psoriasis. Renal dysfunction. Transplant recipients. Elderly. Debilitated. Pregnancy (Cat.C). Nursing mothers: not recommended.

Interactions:

Caution with myelosuppressives, and drugs that can exacerbate depression. May potentiate theophylline (may double its levels).

See Also:

INTRON A

Pharmacological Class:

Alpha interferon.

Adverse Reactions:

Flu-like symptoms (fever, headache, myalgia, fatigue); hepatic, hematologic, respiratory, skin, genitourinary system, CNS, cardiovascular, endocrine (esp. thyroid), GI, or visual disorders; colitis, hypertriglyceridemia, pancreatitis, infections, injection site reactions, dental and periodontal disorders; others (see full labeling).

How Supplied:

Pwd (w. diluent): 10million, 18million, 50million IU/vial—1; Soln (multidose vials): 18million, 25million IU/vial—1

Indications for INTRON A SOLN:

Genital warts.

Adult:

Use appropriate preparation and route: see full labeling. Use SC route if platelets <50,000/mm3. Inject intralesionally 1 million IU/lesion 3 times weekly on alternate days for 3 weeks; treat up to 5 lesions at one time. May repeat treatment as above after 12–16 weeks.

Children:

Not recommended.

Contraindications:

Decompensated liver disease. Autoimmune hepatitis.

Warnings/Precautions:

May cause or exacerbate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, or infectious disorders: monitor closely, discontinue if they worsen. Severe psychiatric disorders (esp. depression). Cardiovascular or pulmonary disease. Severe myelosuppression; discontinue if neutrophil count <0.5 X109/L or platelets 25X109/L. Permanently discontinue if severe (Grade 3) hepatic injury or decompensation (Child-Pugh score >6 [Class B and C]) develop. Thyroid abnormalities; discontinue if uncontrolled by medication. Diabetes. Coagulation disorders. Maintain adequate hydration. Monitor blood, thyroid, visual and liver function before and during therapy; EKG in cardiovascular disease and cancer patients. Psoriasis. Renal dysfunction. Transplant recipients. Elderly. Debilitated. Pregnancy (Cat.C). Nursing mothers: not recommended.

Interactions:

Caution with myelosuppressives, and drugs that can exacerbate depression. May potentiate theophylline (may double its levels).

See Also:

INTRON A

Pharmacological Class:

Alpha interferon.

Adverse Reactions:

Flu-like symptoms (fever, headache, myalgia, fatigue); hepatic, hematologic, respiratory, skin, genitourinary system, CNS, cardiovascular, endocrine (esp. thyroid), GI, or visual disorders; colitis, hypertriglyceridemia, pancreatitis, infections, injection site reactions, dental and periodontal disorders; others (see full labeling).

How Supplied:

Pwd (w. diluent): 10million, 18million, 50million IU/vial—1; Soln (multidose vials): 18million, 25million IU/vial—1